|
시장보고서
상품코드
1402471
중남미의 방사성 의약품 테라노스틱스 시장 예측(-2028년) : 지역별 분석 - 제품 유형별, 방사성동위원소별, 선원별, 용도별, 적응증별, 최종사용자별South & Central America Radiopharmaceutical Theranostics Market Forecast to 2028 - Regional Analysis - by Product Type, Radioisotope ; Source, Application ; Indication, and End User |
||||||
중남미의 방사성 의약품 테라노스틱스 시장은 2022년에 1억 2,948만 달러로 평가되며, 2028년에는 2억 3,371만 달러에 달할 것으로 예측되며, 2022-2028년의 CAGR은 10.3%로 추정됩니다.
개별화 방사성 의약품 치료를 위한 테라노스틱 디지털 트윈이 중남미의 방사성 의약품 테라노스틱스 시장을 촉진
방사성 의약품 치료(RPT)는 치료를 받는 모든 환자에게 특정 방사성 약물(예: Lu-177-PSMA 또는 Lu-177-DOTATATE의 경우 200mCi)을 주사합니다. 그러나 주사를 통해 장기에 전달되는 선량이나 흡수되는 약물의 질은 매우 다양합니다. 종양이나 정상 조직에 대한 방사성의약품 치료는 흡수량에 따라 달라지지만, 흡수량의 편차를 제어하는 것은 어렵습니다. 그러나 흡수량의 변동은 통제하기 어렵습니다. 용량을 고정하면 환자의 치료가 불충분하고 선량 독성을 유발할 수 있습니다. 이러한 제약을 극복하기 위해 약물 개발 과정에서 TDT(Theranostic Digital Twin, Theranostic Digital Twin)를 사용할 수 있으며, TDT는 방사성 약물의 주입 간격과 프로파일, 적절한 방사성 약물 병용 요법을 결정하고 환자 간 최적의 방사성 약물 주입 부위를 조사했습니다.을 조사했습니다. 또한 TDT는 적절한 계산 툴와 결합하여 흡수선량 예측 모델링에 사용할 수 있습니다. 또한 TDT는 생성된 임상 결과의 불확실성을 제로로 만들 수 있으므로 환자에게 진정으로 개인화된 치료를 제공하는 강력한 툴로 작용할 수 있습니다. 따라서 개별화된 방사성의약품 치료에서 TDT의 사용은 방사성의약품 테라노스틱스 시장 기업에게 유리한 기회를 제공합니다.
중남미 방사성의약품 테라노스틱스 시장 개요
중남미 방사성의약품 테라노스틱스 시장은 아르헨티나, 브라질, 기타 중남미로 구분됩니다. 이 지역 시장 성장은 암과 심혈관 질환의 유병률 증가와 정부의 지원 계획의 존재에 기인합니다. 심혈관 질환에 취약한 당뇨병 환자 증가는 브라질의 방사성의약품 세라노스틱 시장의 성장을 가속하고 있습니다. 또한 브라질의 보건의료 지출 증가는 방사성의약품 테라노스틱스 시장을 촉진하고 있습니다.
중남미의 방사성 의약품 테라노스틱스 시장 매출과 2028년까지의 예측(금액)
중남미의 방사성 의약품 테라노스틱스 시장 세분화
중남미의 방사성 의약품 테라노스틱스 시장은 제품 유형, 방사성 동위체, 선원, 용도, 적응증, 최종사용자, 국가에 의해 구분됩니다. 제품 유형별로 보면 중남미의 방사성 의약품 테라노스틱스 시장은 알파 선방출 핵종, 베타 선방출 핵종, 양전자방출단층촬영(PET) 트레이서로 구분됩니다. 양전자방출단층촬영(PET) 트레이서 부문이 2022년에 최대 시장 점유율을 차지했습니다.
방사성 의약품 테라노스틱스 시장은 방사성 유형별로 테크네튬-99, 갈륨-68, 요오드-131, 요오드-123, 불소-18(18 F), 이트륨 90(Y-90), 루테튬(Lu) 177, 구리(Cu) 67, 구리(Cu) 64, 기타로 구분됩니다. 루테튬(Lu) 177 부문이 2022년에 최대 시장 점유율을 차지했습니다.
방사성 의약품 테라노스틱스 시장은 선원에 기반하여 원자로와 사이클로트론으로 구분됩니다. 사이클로트론 부문이 2022년에 큰 시장 점유율을 차지했습니다.
용도별로는 중남미의 방사성 의약품 테라노스틱스 시장은 표적 치료[Rx]와 동반진단[CDx]으로 구분됩니다. 2022년에는 표적 치료[Rx] 분야가 보다 큰 시장 점유율을 차지했습니다.
적응증에 기반하여 중남미의 방사성 의약품 테라노스틱스 시장은 종양학, 순환기학, 신경학, 기타로 구분됩니다. 2022년에는 종양 분야가 최대 시장 점유율을 차지했습니다.
최종사용자별로 보면 중남미의 방사성 의약품 테라노스틱스 시장은 병원, 영상 진단 센터, 학술·연구기관, 기타로 구분됩니다. 병원 부문이 2022년에 최대 시장 점유율을 차지했습니다.
국가별로는 중남미의 방사성 의약품 테라노스틱스 시장은 브라질, 아르헨티나, 기타 남미로 구분됩니다. 브라질은 2022년 중남미의 방사성 의약품 테라노스틱스 시장 점유율을 독점했습니다.
Bayer AG, Curium, Telix Pharmaceuticals Ltd., Siemens Healthineers 등이 남미·중앙아메리카의 방사성 의약품 테라노스틱스 시장에서 사업을 운영하는 대기업입니다.
목차
제1장 서론
제2장 중남미의 방사성 의약품 테라노스틱스 시장 : 주목점
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 중남미의 방사성 의약품 테라노스틱스 시장 : 시장 구도
- PEST 분석
- 중남미의 PEST 분석
- 전문가의 견해
제5장 방사성 의약품 테라노스틱스 시장 : 주요 시장 역학
- 시장 촉진요인
- 암이환율의 상승
- 심혈관질환 치료에 대한 응용 확대
- 시장 억제요인
- 방사성 의약품 테라노스틱스 승인을 향한 규제 과제
- 시장 기회
- 개별화 방사성 의약품 치료를 위한 테라노스틱 디지털 트윈
- 향후 동향
- 핵의학용 방사성 의약품 테라노스틱스
- 영향 분석
제6장 방사성 의약품 테라노스틱스 시장 : 중남미 분석
- 중남미의 방사성 의약품 테라노스틱스 시장 매출과 예측 분석
제7장 중남미의 방사성 의약품 테라노스틱스 시장 : 제품 유형별 매출과 2028년까지의 예측
- 방사성 의약품 테라노스틱스 시장 매출 점유율(2021년·2028년)
제8장 방사성 의약품 테라노스틱스 중남미 시장 분석 : 방사성동위원소별
- 방사성 의약품 테라노스틱스 시장 매출 점유율(2021년·2028년)
제9장 중남미의 방사성 의약품 테라노스틱스 시장 분석 : 선원별
- 방사성 의약품 테라노스틱스 시장 매출 점유율(2021년·2028년)
제10장 중남미의 방사성 의약품 테라노스틱스 시장 분석 : 용도별
- 방사성 의약품 테라노스틱스 시장 매출 점유율(2021년·2028년)
제11장 중남미의 방사성 의약품 테라노스틱스 시장 분석 : 적응증별
- 방사성 의약품 테라노스틱스 시장 매출 점유율(2021년·2028년)
제12장 중남미의 방사성 의약품 테라노스틱스 시장 분석 : 최종사용자별
- 방사성 의약품 테라노스틱스 시장 매출 점유율(2021년·2028년)
제13장 중남미의 방사성 의약품 테라노스틱스 시장 - 매출과 2028년까지의 예측 : 국가별 분석
제14장 방사성 의약품 테라노스틱스 시장 : 업계 상황
- 방사성 의약품 테라노스틱스 시장에서의 성장 전략
- 무기적 성장 전략
- 유기적 성장 전략
제15장 기업 개요
- Bayer AG
- Curium
- Telix Pharmaceuticals Ltd.
- Siemens Healthineers AG
제16장 부록
KSA 24.01.12The South & Central America radiopharmaceutical theranostics market was valued at US$ 129.48 million in 2022 and is expected to reach US$ 233.71 million by 2028; it is estimated to register a CAGR of 10.3% from 2022 to 2028.
Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies fuel the South & Central America Radiopharmaceutical Theranostics Market
Radiopharmaceutical therapies (RPTs) involve injecting a particular radioactive drug (such as 200mCi for Lu-177-PSMA and Lu-177-DOTATATE) into all patients undergoing therapy. However, upon injection, the doses delivered to organs and absorbed qualities of drugs show notable variations. Radiopharmaceutical therapies for tumors and normal tissues depend on absorbed doses; however, variations in absorption are difficult to control. A fixed administered dosage results in the undertreatment of patients, possibly leading to cases of dose toxicity. Theranostic digital twins (TDTs) can be employed in the drug development process to overcome such limitations. The TDTs investigate optimal injected radioactive drugs among patients at the sites of injection, along with determining injection intervals and profiles, and suitable combinational radiopharmaceutical therapies. Additionally, TDTs coupled with appropriate computational tools can be used in predictive absorbed radiation dose modeling. Further, TDTs promise zero uncertainties in the clinical results generated, thus acting as a powerful tool for offering truly personalized treatments to patients. Thus, the use of TDTs in personalized radiopharmaceutical therapies provides lucrative opportunities for radiopharmaceutical theranostics market players.
South & Central America Radiopharmaceutical Theranostics Market Overview
The South & Central America radiopharmaceutical theranostics market is segmented into the Argentina, Brazil, and the rest of South & Central America. The market growth in this region is due to the increasing prevalence of cancer and cardiovascular diseases, and presence of supportive government plans. Growing diabetes who are prone to cardiovascular disease is promoting the growth of radiopharmaceutical theranostics market in Brazil. Further, expanding healthcare expenditure in Brazil is boosting the radiopharmaceutical theranostics market.
South & Central America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)
South & Central America Radiopharmaceutical Theranostics Market Segmentation
The South & Central America radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the South & Central America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.
Based on radioisotype, the South & Central America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.
Based on indication, the South & Central America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the South & Central America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America radiopharmaceutical theranostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America radiopharmaceutical theranostics market share in 2022.
Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the South & Central America radiopharmaceutical theranostics market.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central Americaradiopharmaceutical theranostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the South & Central Americaradiopharmaceutical theranostics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central Americaradiopharmaceutical theranostics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table Of Contents
1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 South & Central America Radiopharmaceutical Theranostics Market - by Product Type
- 1.3.2 South & Central America Radiopharmaceutical Theranostics Market - by Radioisotope
- 1.3.3 South & Central America Radiopharmaceutical Theranostics Market - by Source
- 1.3.4 South & Central America Radiopharmaceutical Theranostics Market - by Application
- 1.3.5 South & Central America Radiopharmaceutical Theranostics Market - by Indication
- 1.3.6 South & Central America Radiopharmaceutical Theranostics Market - by End User
- 1.3.7 South & Central America Radiopharmaceutical Theranostics Market - by Country
2. South & Central America Radiopharmaceutical Theranostics Market - Key Takeaways
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. South & Central America Radiopharmaceutical Theranostics Market - Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 South & Central America PEST Analysis
- 4.3 Expert's Opinion
5. South & Central America Radiopharmaceutical Theranostics Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Rising Incidence of Cancer
- 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
- 5.2 Market Restraints
- 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
- 5.3 Market Opportunities
- 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
- 5.4 Future Trends
- 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
- 5.5 Impact Analysis
6. Radiopharmaceutical Theranostics Market - South & Central America Analysis
- 6.1 South & Central America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
7. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type
- 7.1 Overview
- 7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
- 7.2.1 Positron Emission Tomography (PET) Tracers
- 7.2.1.1 Overview
- 7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.2 Beta Emitters
- 7.2.2.1 Overview
- 7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.3 Alpha Emitters
- 7.2.3.1 Overview
- 7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.1 Positron Emission Tomography (PET) Tracers
8. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Radioisotope
- 8.1 Overview
- 8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
- 8.2.1 Technetium-99
- 8.2.1.1 Overview
- 8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.2 Gallium-68
- 8.2.2.1 Overview
- 8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Iodine-131
- 8.2.3.1 Overview
- 8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.4 Iodine-123
- 8.2.4.1 Overview
- 8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.5 Fluorine-18 (18F)
- 8.2.5.1 Overview
- 8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.6 Yttrium 90 (Y-90)
- 8.2.6.1 Overview
- 8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.7 Lutetium (LU) 177
- 8.2.7.1 Overview
- 8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.8 Copper (CU) 67
- 8.2.8.1 Overview
- 8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.9 Copper (CU) 64
- 8.2.9.1 Overview
- 8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.10 Others
- 8.2.10.1 Overview
- 8.2.10.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.1 Technetium-99
9. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Source
- 9.1 Overview
- 9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
- 9.2.1 Nuclear Reactors
- 9.2.1.1 Overview
- 9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.2 Cyclotrons
- 9.2.2.1 Overview
- 9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.1 Nuclear Reactors
10. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Application
- 10.1 Overview
- 10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
- 10.2.1 Targeted Therapeutic (Rx)
- 10.2.1.1 Overview
- 10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 10.2.2 Companion Diagnostic (CDx)
- 10.2.2.1 Overview
- 10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 10.2.1 Targeted Therapeutic (Rx)
11. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Indication
- 11.1 Overview
- 11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
- 11.2.1 Oncology
- 11.2.1.1 Overview
- 11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.2 Neurology
- 11.2.2.1 Overview
- 11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.3 Cardiology
- 11.2.3.1 Overview
- 11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.4 Others
- 11.2.4.1 Overview
- 11.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.1 Oncology
12. South & Central America Radiopharmaceutical Theranostics Market Analysis - by End User
- 12.1 Overview
- 12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
- 12.2.1 Hospitals
- 12.2.1.1 Overview
- 12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.2 Diagnostic Imaging Centers
- 12.2.2.1 Overview
- 12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.3 Academic & Research Institutes
- 12.2.3.1 Overview
- 12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.4 Others
- 12.2.4.1 Overview
- 12.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.1 Hospitals
13. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis
- 13.1 South & Central America Radiopharmaceutical Theranostics Market
- 13.1.1 Overview
- 13.1.2 South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
- 13.1.2.1 Brazil: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.2.1.1 Overview
- 13.1.2.1.2 Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.2.1.3 Brazil Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
- 13.1.2.1.4 Brazil Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.1.2.1.5 Brazil Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.1.2.1.6 Brazil Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.1.2.1.7 Brazil Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.1.2.1.8 Brazil Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.1.2.2 Argentina: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.2.2.1 Overview
- 13.1.2.2.2 Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.2.2.3 Argentina Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.1.2.2.4 Argentina Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.1.2.2.5 Argentina Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.1.2.2.6 Argentina Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.1.2.2.7 Argentina Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.1.2.2.8 Argentina Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.1.2.3 Rest of South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.2.3.1 Overview
- 13.1.2.3.2 Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.2.3.3 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.1.2.3.4 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.1.2.3.5 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.1.2.3.6 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.1.2.3.7 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.1.2.3.8 Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.1.2.1 Brazil: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
14. Radiopharmaceutical Theranostics Market - Industry Landscape
- 14.1 Overview
- 14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
- 14.3 Inorganic Growth Strategies
- 14.3.1 Overview
- 14.4 Organic Growth Strategies
- 14.4.1 Overview
15. Company Profiles
- 15.1 Bayer AG
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
- 15.2 Curium
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
- 15.3 Telix Pharmaceuticals Ltd.
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
- 15.4 Siemens Healthineers AG
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
16. Appendix
- 16.1 About The Insight Partners
- 16.2 Glossary of Terms
